177Lu-DOTAGA-(l-y)fk(Sub-KuE) (177Lu-PSMA I&T) is currently used for
radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC)
in several centers in Europe. It was launched in Tallinn, Estonia, in December 2018. As
an additional project, a model of dosimetric analysis was created, utilizing voxel-based
dosimetry and intra-lesion radiomics to assess their practicality in routine dosimetry
. This was a successful project, and the work is summarized in this chapter.
Keywords: 177Lu isotope, Dosimetry, Positron emission tomography, Prostate cancer, PSMA, Quantitative SPECT, Radiomics, Radionuclide therapy, Voxelbased dosimetry.